Inflammatory Bowel Diseases (Inflammatory Bowel Disease)

01/01/2018 - "The Trough Concentration Adapted Infliximab Treatment (TAXIT) trial demonstrated that maintaining infliximab trough concentrations at 3 to 7 μg/mL is most effective at inducing remission in patients with inflammatory bowel diseases (IBDs), with fewer flares than clinic-based dosing. "
02/18/2021 - "High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study."
01/01/2019 - "Therapeutic drug monitoring (TDM) of infliximab (IFX) appears to be beneficial for patients with inflammatory bowel disease (IBD). "
08/01/2016 - "Infliximab, the first anti-TNF-α biologic drug, has significantly improved inflammatory bowel disease (IBD) treatment outcomes by preventing structural damage progression, thereby reducing complications and the need for surgery and hospitalization. "
02/01/2016 - "The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease."

10/26/2023 - "Specifically, the introduction of anti-tumor necrosis factor (TNF) drugs has changed the approach to the treatment of inflammatory bowel disease, and set new therapeutic goals, such as that of controlling clinical symptoms while simultaneously achieving complete endoscopic and mucosal remission. "
01/01/2022 - "Significant advantages for first line treatment with TNF-alpha inhibitors in pediatric patients with inflammatory bowel disease - Data from the multicenter CEDATA-GPGE registry study."
08/07/2023 - "Tumor necrosis factor-α (TNF-α) antagonists, the first biologics approved for treating patients with inflammatory bowel disease (IBD), are effective for the induction and maintenance of remission and significantly improving prognosis. "
01/01/2016 - "After the introduction of anti-tumor necrosis factor (anti-TNF) agents, the clinical outcome of patients with Inflammatory Bowel Disease (IBD) has improved significantly. "
06/18/2005 - "The introduction of immunosuppressors and anti-TNF alpha agents for chronic inflammatory bowel diseases constitutes a major advance in the management of their severe forms, but nevertheless raises the issues of whether their use should be systematic or depend on the severity of the disease. "

06/01/2013 - "Azathioprine is the most common drug used to maintain clinical remission in inflammatory bowel disease. "
09/01/2023 - "Azathioprine (AZA) forms the cornerstone for maintenance of sustained remission in inflammatory bowel disease (IBD). "
07/01/2019 - "Azathioprine is widely used for the maintenance of remission in children with inflammatory bowel disease (IBD). "
01/01/2014 - "Azathioprine (AZA) is widely used for the treatment of inflammatory bowel disease (IBD) patients. "
11/01/2003 - "Azathioprine (AZA) is an effective treatment for inflammatory bowel disease. "

01/01/2018 - "The humanized form of Rh-α4β7, vedolizumab, is a highly effective treatment for inflammatory bowel disease. "
10/01/2020 - "Inflammatory bowel disease (IBD) can be successfully treated with vedolizumab. "
02/01/2020 - "Although the treatment is beneficial for inflammatory bowel disease (IBD), the effects of vedolizumab on extraintestinal manifestations (EIMs) have not been well described. "
03/01/2020 - "The GEMINI trials established the efficacy of vedolizumab in moderate-to-severe inflammatory bowel disease (IBD) and demonstrated a favorable safety profile, suggesting it may be advantageous in older patients at greater risk of treatment-related complications. "
01/01/2022 - "Higher serum concentrations of vedolizumab have been associated with improved outcomes in inflammatory bowel disease. "

09/15/2008 - "To seek evidence and provide direction for clinicians on optimal strategies to enable steroid free remission in inflammatory bowel disease. "
03/20/2023 - "Systemic steroid exposure, while useful for the treatment of acute flares in inflammatory bowel disease (IBD), is associated with an array of side effects that are particularly significant in children. "
01/01/2021 - "Pediatric patients with inflammatory bowel disease on anti-TNF monotherapy who started an IM for significant ADA levels exhibited longer anti-TNF durability and a higher likelihood of steroid-free clinical and biochemical remission on the same anti-TNF. "
10/01/2022 - "Thiopurines are recommended for maintenance of steroid-free remission (SFR) in inflammatory bowel disease (IBD). "
01/01/2021 - "Outcomes included remission, endoscopic improvement, clinical response, sustained steroid-free remission, Inflammatory Bowel Disease Questionnaire total score and Short Form-36 Health Survey scores. "

10/01/1989 - "Improved treatment of individuals with severe inflammatory bowel disease with potent immunosuppressive medications such as 6-mercaptopurine has been previously demonstrated. "
06/04/2019 - "Importantly, a small percentage of adaptable cells survived a low-dose 6-mercaptopurine treatment in a reversible quiescence, analogous to the persistence of abnormal progenitor-like cells in inflammatory bowel disease, which stays in a durable remission with a 6-mercaptopurine treatment. "
11/01/2010 - "6-mercaptopurine (6-MP) is used for the induction and maintenance of remission of inflammatory bowel disease (IBD). "
11/01/1995 - "[Efficacy of 6-mercaptopurine in the treatment of inflammatory bowel disease]."
10/15/1989 - "Our data, showing a low incidence of toxicity in 396 patients, coupled with the previously demonstrated efficacy of 6-mercaptopurine in the treatment of inflammatory bowel disease, indicate that the drug is a reasonable alternative in the management of patients with intractable inflammatory bowel disease."

10/01/1994 - "These studies strongly suggest that mesalazine microgranules are effective for idiopathic inflammatory bowel disease."
04/01/2013 - "5-aminosalicylic acid (5-ASA) is widely used for the treatment of inflammatory bowel disease (IBD). "
07/01/2003 - "Mesalazine (Salofalk) was found to be effective and showed low toxicity in patients with inflammatory bowel disease. "
10/01/2001 - "Mesalamine (5-ASA) is effective in the treatment of inflammatory bowel diseases. "
09/01/2000 - "5-Aminosalicylic acid is an effective treatment for patients with inflammatory bowel disease. "

10/01/2003 - "In initial independent clinical studies, these two new models have produced striking clinical efficacy, safety, and a marked reduction in the dose of corticosteroids used to induce remission of active inflammatory bowel disease. "
01/01/2021 - "Corticosteroids remain an important tool for inducing remission in inflammatory bowel disease (IBD) but they have no role in maintenance of remission. "
01/14/2023 - "In women with inflammatory bowel disease, at least 3 months of preconception corticosteroid-free remission (CFREM) is recommended by experts in current consensus statements. "
09/01/2006 - "We further examined whether these resulted in better selection of the drug dose, improved control of disease, and decreased corticosteroid use in pediatric inflammatory bowel disease (IBD). "
01/01/2021 - "Corticosteroids are effective for inducing clinical remission in inflammatory bowel disease (IBD), but not for maintaining remission. "

01/31/2009 - "Furthermore, through downregulation of proinflammatory cytokines, Enprocal appears to be beneficial in reducing the effects of chronic gut inflammatory diseases such as inflammatory bowel disease (IBD). "
11/01/2022 - "Recent scientific advances helped to unravel the pathophysiology of inflammatory bowel disease and newer cytokines have been identified which can be potential targets in the management of IBD. "
06/01/2005 - "Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells."
12/01/2017 - "Previous studies have revealed that mesenchymal stem cells (MSCs) alleviate inflammatory bowel disease (IBD) by modulating inflammatory cytokines in the inflamed intestine. "
01/01/2017 - "Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases."

09/01/2011 - "Thiopurine drugs are the most common drugs used to maintain clinical remission in inflammatory bowel disease (IBD). "
01/01/2010 - "The efficacy of thiopurine treatment in the induction, and especially maintenance, of remission in inflammatory bowel disease is well proven; however, it is associated with side effects in both medium and long-term use. "
01/01/2018 - "The review is concluded with suggestions for future work aiming at using a more comprehensive approach to optimize the efficacy of thiopurine compounds in inflammatory bowel disease."
03/01/2015 - "Letter: Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease."
01/01/2015 - "Editorial: thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease."

01/01/2022 - "Nearly one-third of patients with inflammatory bowel disease (IBD) do not achieve remission despite our best therapies. "
01/01/2019 - "The older patient group with inflammatory bowel diseases (IBD) is particularly vulnerable to consequences of disease and therapy-related side effects but little is known about the best treatment options in this population. "
09/23/2016 - "Although FMT appears to be safe and highly effective in patients with a preserved colon and immunocompetence, its use in patients with inflammatory bowel disease (IBD) who are on immunomodulating therapies is controversial. "
10/01/2007 - "The introduction of biologic agents to the therapeutic arsenal has dramatically impacted the way we treat patients with inflammatory bowel disease, allowing clinicians to achieve lasting remission in patients who are unresponsive to conventional therapies. "
01/01/2023 - "Thiopurines are an important therapy for the maintenance of remission in inflammatory bowel disease (IBD). "

11/16/2023 - "Biological therapy is very effective for treating patients with moderate to severe inflammatory bowel disease (IBD). "
04/01/2013 - "Introduction of biologic therapy in clinical practice represented significant progress in the treatment of inflammatory bowel diseases (IBD) because of its proven efficacy and due to the fact that biologics are the first drugs used in the treatment of IBD that can change the natural course of this diseases. "
06/01/2017 - "The introduction of biologic therapies has revolutionized the treatment of inflammatory bowel disease (IBD) and has significantly improved the disease course and outcomes for many patients. "
10/01/2023 - "Higher Intra-Abdominal Visceral Adipose Tissue Mass Is Associated With Lower Rates of Clinical and Endoscopic Remission in Patients With Inflammatory Bowel Diseases Initiating Biologic Therapy: Results of the Constellation Study."
09/22/2023 - "Comments on "Higher Intra-Abdominal Visceral Adipose Tissue Mass Is Associated With Lower Rates of Clinical and Endoscopic Remission in Patients With Inflammatory Bowel Diseases Initiating Biologic Therapy: Results of the Constellation Study"."

01/01/2022 - "Fecal microbiota transplantation (FMT) has been seen as a novel treatment for inflammatory bowel disease (IBD). "
01/01/2021 - "Fecal microbiota transplantation as a new treatment for canine inflammatory bowel disease."
12/01/2014 - "Fecal microbiota transplantation (FMT) has gained interest as a novel treatment option for inflammatory bowel diseases (IBD). "
05/12/2023 - "Safety and Efficacy of Fecal Microbiota Transplantation in Treatment of Inflammatory Bowel Disease in the Pediatric Population: A Systematic Review and Meta-Analysis."
01/01/2021 - "IMPORTANCE Fecal microbiota transplantation (FMT)-transferring fecal microbes from a healthy donor to a sick patient-has shown promise for gut diseases such as inflammatory bowel disease. "

11/01/2019 - "Secondary endpoints included endoscopic remission (endoscopic Mayo score of 1 or less), failure (colectomy or start of experimental medication), and changes in Inflammatory Bowel Disease Questionnaire (IBDQ) (range 32-224), EQ-5D™ and EORTC-QLQ-C30-QL scores. "
11/08/2023 - "Colectomy and reconstruction in patients with inflammatory bowel disease [IBD] may adversely affect fertility, but few population-based studies on this subject are available. "
01/01/2023 - "Short-term outcomes following total colectomy for inflammatory bowel disease in Denmark after implementation of laparoscopy: a nationwide population-based study."
07/01/2021 - "Out of these, 372 were included in the study based on the following exclusion criteria: being under 18 years of age, inadequate bowel preparations (Boston scale <7), history of colectomy, inflammatory bowel disease or polypoid diseases. "
05/01/2015 - "The Pubmed and Embase databases were searched using the terms "inflammatory bowel disease," "children," "adolescents," "laparoscopic," and "colectomy." The review identified 10 appropriate studies. "

12/01/2011 - "Leukocytes are thought to play an important role in the pathogenesis of inflammatory bowel diseases; granulocyte-monocyte adsorptive (GMA) apheresis, an extracorporeal technique aimed at removing activated circulating leukocytes from the blood, may represent a safe and effective therapeutic tool in these patients. "
10/01/2008 - "We assessed whether selective granulocyte and monocyte/macrophage adsorption apheresis maintained clinical remission in asymptomatic inflammatory bowel disease (IBD) patients at significant risk of clinical relapse. "
12/01/2016 - "Efficacy of a Novel Granulocyte Monocyte Apheresis Adsorber Device in the Treatment of Inflammatory Bowel Diseases: A Pilot Study."
01/01/2012 - "Adsorptive granulocyte apheresis (GCAP) is a new treatment for inflammatory bowel disease. "
01/01/2012 - "The present reviews analyzes the data on the safety and efficacy of apheresis in those patients with inflammatory bowel diseases who could benefit from this technique."